Curated News:

Medical Meetings

Add to Favorites Subscribe Share
fbshare-Medical Meetings

Showing results

36113620 of 3750
mmc-logo.gif

Article ID: 608044

Drug Fails to Reduce Diarrhea in Patients Receiving Radiation Therapy

Mayo Clinic

Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found. The study also found that the medication may be associated with a higher risk of diarrhea than a placebo when used during radiation therapy to the pelvis. The results were presented today at the American Society of Radiation Oncology’s (ASTRO’s) 55th Annual Meeting in Atlanta.

Released:
23-Sep-2013 2:00 PM EDT
ato-logo.gif

Article ID: 608008

Long-Term Hormonal Therapy in Intermediate-Risk Prostate Cancer Patients Does Not Improve Overall Survival

American Society for Radiation Oncology (ASTRO)

A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

Released:
23-Sep-2013 10:45 AM EDT
  • Embargo expired:
    23-Sep-2013 8:30 AM EDT

Article ID: 607809

Simple, Two-Question Survey Accurately Screens Cancer Patients for Depression

Loyola University Health System

Cancer patients can be accurately screened for major depression with a simple two-question survey, according to a study presented Sept. 23 at the American Society for Radiation Oncology’s 55th Annual Meeting.

Released:
18-Sep-2013 11:00 AM EDT
ato-logo.gif

Article ID: 607990

Patient-Reported Outcomes Provide Valuable Insight Regarding Quality of Life for Patients with Non-Small Cell Lung Cancer

American Society for Radiation Oncology (ASTRO)

An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

Released:
23-Sep-2013 8:30 AM EDT
ato-logo.gif

Article ID: 607991

Avoiding Specific Region of Brain During Whole-Brain Radiotherapy Prevents Memory Loss

American Society for Radiation Oncology (ASTRO)

Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

Released:
23-Sep-2013 8:30 AM EDT
ato-logo.gif

Article ID: 607992

Fewer Weeks of Hormone Therapy Before Radiation Treatment Reduces Side Effects and Yields Comparable Disease-Specific-Survival for Intermediate Risk Prostate Cancer Patients

American Society for Radiation Oncology (ASTRO)

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology’s (ASTRO) 55th Annual Meeting.

Released:
23-Sep-2013 8:30 AM EDT
ato-logo.gif

Article ID: 607993

Two-Item Questionnaire Proves to Be a Valid Depression Screening Tool for Radiation Therapy Patients

American Society for Radiation Oncology (ASTRO)

Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

Released:
23-Sep-2013 8:30 AM EDT
ato-logo.gif

Article ID: 607987

ASTRO and AUA Joint Guideline for Radiation Therapy After Prostatectomy Highlighted at ASTRO Annual Meeting

American Society for Radiation Oncology (ASTRO)

The American Society for Radiation Oncology (ASTRO) will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO’s 55th Annual Meeting, September 22-25, 2013, in Atlanta.

Released:
22-Sep-2013 6:15 PM EDT
ato-logo.gif

Article ID: 607986

Adult Cancer Patients Younger Than 50 Presenting with a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone

American Society for Radiation Oncology (ASTRO)

When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

Released:
22-Sep-2013 3:00 PM EDT
ato-logo.gif

Article ID: 607985

Proton Therapy Is a Cost-Effective Treatment for Pediatric Brain Tumor Patients

American Society for Radiation Oncology (ASTRO)

Proton therapy, an external beam radiotherapy in which protons deliver precise radiation doses to a tumor and spare healthy organs and tissues, is cost-effective in treating medulloblastomas, fast-growing brain tumors that mainly affect children, when compared to standard photon radiation therapy, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

Released:
22-Sep-2013 2:35 PM EDT

Showing results

36113620 of 3750

Chat now!